Market evolution: Penicillin antibiotics (CN 300410) — 2015–2025

Introduction

This report examines the evolution of EU trade in penicillin-based antibiotics (Customs Nomenclature code 300410) over the period 2015–2025. The product covers medicaments containing penicillins or derivatives thereof with a penicillanic acid structure, or streptomycins or derivatives thereof, put up in measured doses or in forms for retail sale. The EU remains a major global player in this segment: in 2025, exports reached €839.2 million, while imports stood at €159.0 million, yielding a trade surplus of €680.2 million. Over the full decade, however, the market has undergone a profound structural transformation: traded volumes have contracted sharply while unit values have surged, the geographic composition of both imports and exports has shifted significantly, and the EU's net export position has deepened considerably. Three main dynamics stand out: a price-driven value structure replacing volume-driven growth; a geographic diversification of suppliers coupled with a reshuffling of export destinations; and a strengthening of the EU's strategic autonomy as an exporter, even as certain supply-chain vulnerabilities persist.

1. Declining volumes, surging prices: the structural transformation of trade value

The most striking feature of the 2015–2025 period is the divergence between traded volumes and traded values. On the export side, EU shipments of CN 300410 fell from 25,431 tonnes in 2015 to 18,488 tonnes in 2025 — a decline of 27.3% — yet the total export value edged up from €788.6 million to €839.2 million (+6.4%). The explanation lies in a dramatic rise in export unit values, which climbed from approximately €31,009 per tonne to €45,384 per tonne (+46.4%). On the import side, the pattern is even more pronounced: import volumes collapsed by 61.3%, from 4,609 tonnes to just 1,782 tonnes, while the import value barely budged (from €161.9 million to €159.0 million, a modest -1.8%). This is because import unit prices more than doubled, soaring from €35,106 per tonne to €89,045 per tonne (+153.6%).

1.1 Volume contraction reflects a mature, consolidating market

The decline in traded volumes — both on the export and import sides — is consistent with a maturing antibiotics market. Penicillins are among the oldest classes of antibiotics, and global demand growth has plateaued relative to newer antimicrobial classes. Additionally, tighter regulatory controls on antibiotic stewardship in the EU and elsewhere have contributed to restraining volume growth. The fact that EU production value fell from an estimated €1,607 million in 2015 to €900 million in 2025 (−44.0%) further confirms that the industry is producing and shipping smaller physical quantities.

1.2 Price inflation signals product-mix upgrading and cost pressures

The 46.4% rise in export unit values and the 153.6% rise in import unit values point to several concurrent forces. First, the product mix has likely shifted toward higher-value formulations — for example, combination products, extended-release forms, or transdermal presentations — which command higher per-kilogram prices. Second, raw-material and active-ingredient costs have risen globally, partly due to supply-chain disruptions during and after the COVID-19 pandemic (2020–2021). Third, the exceptionally high import unit price in 2025 (€89,045/t) compared to the export unit price (€45,384/t) suggests that the EU imports more specialised or higher-margin penicillin preparations, while exporting more standardised bulk finished-dose forms.

2. Geographic diversification of suppliers and reshuffling of export destinations

Over the 2015–2025 decade, the geographic composition of both the EU's import sources and export destinations underwent substantial change. Import concentration fell sharply (the Herfindahl–Hirschman Index for import value declined from 6,633 to 3,534, −46.7%), indicating a deliberate diversification of supply chains. Export concentration also fell, albeit from already-low levels (HHI from 879 to 492, −44.0%).

2.1 The UK's declining share and the rise of Asian suppliers

The United Kingdom was the EU's largest supplier of CN 300410 imports in 2015, accounting for €126.6 million. By 2025, UK imports had fallen to €77.8 million (−38.6%), though the UK remained the top single-country supplier. This decline is partly attributable to the post-Brexit reconfiguration of trade flows and regulatory divergence. Meanwhile, Asian suppliers gained substantial ground:

India's import value more than doubled, rising to €45.4 million, reflecting India's role as a global hub for generic pharmaceutical manufacturing, including active pharmaceutical ingredients (APIs) and finished-dose penicillins. Most strikingly, imports from China surged from a negligible €0.5 million to €26.8 million — a nearly fifty-fold increase. This mirrors China's broader expansion as an exporter of pharmaceutical products and its growing capacity in beta-lactam manufacturing. The volatility analysis reveals that some of these newer suppliers — notably Indonesia (CV 1.41) and the Russian Federation (CV 2.71) — exhibit very high trade volatility, suggesting that the EU's growing reliance on these sources may carry stability risks.

2.2 Export destinations: emerging markets gain weight while traditional partners recede

On the export side, the two largest traditional markets — the United States and the United Kingdom — both saw significant declines:

The US decline of 38.1% (from €180.2 million to €111.6 million) is significant, possibly reflecting increased domestic US production capacity and greater competition from Indian and Chinese generics. In contrast, emerging markets absorbed much larger shares of EU penicillin exports: Viet Nam's imports from the EU grew by 266.5% to €56.5 million, Brazil's by 88.9% to €36.6 million, and the Russian Federation remained a stable large buyer at €87.5 million. This geographic pivot toward Asia and Latin America is a structural shift reflecting changing global demand patterns and the growing healthcare expenditure in developing economies.

2.3 Intra-EU specialisation is concentrated in a handful of member states

Within the EU, export specialisation in penicillin medicaments is highly uneven. In 2025, the most specialised exporters were:

Austria stands out as the EU's dominant penicillin exporter, accounting for 27.4% of the bloc's total export share in this product, with export value rising from €183.6 million in 2015 to €211.1 million in 2025 (+15.0%). Italy also consolidated its position, growing from €83.4 million to €125.0 million (+49.8%). By contrast, Belgium and Slovenia — both historically significant exporters — saw declines of 37.9% and 26.6% respectively. The Netherlands emerged as a fast-growing exporter (from €18.4 million to €45.2 million, +145.5%), likely reflecting its role as a pharmaceutical logistics hub.

3. Deepening export surplus and evolving strategic autonomy

The EU's position as a net exporter of penicillin medicaments has strengthened considerably over the decade. The trade balance widened from €626.7 million in 2015 to €680.2 million in 2025 (+8.5%), and the net import reliance indicator deepened from −19.4% to −339.6%, meaning the EU exports roughly 4.4 times more in value than it imports. The export propensity — the share of production exported outside the EU — surged from 38.4% to 98.8%, while trade intensity rose from 49.6% to 99.0%.

3.1 The EU as a net exporter: near-total external orientation

The near-doubling of trade intensity and the tripling of export propensity suggest that the EU's penicillin production is now almost entirely oriented toward external markets. With 98.8% of production being exported, the EU functions as a specialised production platform for global penicillin supply. This is consistent with the observed decline in production value (from €1,607 million to €900 million) alongside stable-to-rising export values: the EU is producing less overall but channelling a greater share of output abroad, likely at higher unit prices.

3.2 Supply-chain vulnerabilities persist despite diversification

While the falling import HHI indicates meaningful diversification away from the UK as the dominant supplier, several vulnerability indicators warrant attention. Import volatility remains high for several partners — Indonesia (CV 1.41), Russia (CV 2.71), and Egypt (CV 1.64) — meaning that sudden disruptions from these sources are not uncommon. The most significant shock event detected in the dataset was a UK import price shock centred on 2021, with an abnormality score of 92.1 and a 150.3% price shift, affecting 72.1% of import value. This timing coincides with post-Brexit trade friction and COVID-19 supply-chain disruption. A smaller but notable export price shock to the UK occurred in 2017 (+68.0% shift). These events underline that even as the EU diversifies, the penicillin trade remains susceptible to price and volume shocks.

3.3 Balancing export strength with import dependency for specific formulations

The striking gap between import unit values (€89,045/t in 2025) and export unit values (€45,384/t) deserves attention. This gap has widened significantly over the period (import prices rose 153.6% vs. 46.4% for exports), suggesting that the EU imports higher-value-added or niche penicillin preparations while exporting higher-volume, lower-unit-value products. This asymmetry implies that while the EU's overall trade position is strong, it may depend on external suppliers for certain specialised formulations — a potential strategic consideration for pharmaceutical resilience policy.

Conclusion

Over the 2015–2025 period, the EU's trade in penicillin antibiotics (CN 300410) has undergone a fundamental transformation. Traded volumes have declined sharply on both the export and import sides, but rising unit prices — driven by product-mix evolution, cost pressures, and possibly pandemic-era disruptions — have kept trade values broadly stable. The geographic landscape has shifted: the UK's dominant share of EU imports has eroded, making way for a surge in imports from India and especially China, while export destinations have pivoted toward emerging markets such as Viet Nam, Brazil, and the Russian Federation. Within the EU, Austria, Italy, and France have consolidated their positions as the leading penicillin exporters, while some traditional exporters like Belgium have receded. Overall, the EU has deepened its role as a major net exporter, with an export propensity now approaching 100%, though the persistently high unit value of imports suggests ongoing dependency on external sources for certain specialised formulations. The combination of declining import concentration and high import volatility highlights a tension: while supply sources are more diversified than a decade ago, the newer sources carry their own risks. For policymakers, the data suggests that the EU's penicillin export infrastructure is robust and globally competitive, but continued vigilance is warranted regarding the supply chain for higher-value imported preparations and the stability of emerging supplier relationships.